Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지
DOI QR코드

DOI QR Code

Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?

  • Abedi, Siavosh (Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences) ;
  • Janbabaei, Ghasem (Gastrointestinal Cancer Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences) ;
  • Afshari, Mahdi (Department of Community Medicine, Zabol University of Medical Sciences) ;
  • Moosazadeh, Mahmood (Health Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences) ;
  • Alashti, Masoumeh Rashidi (Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences) ;
  • Hedayatizadeh-Omran, Akbar (Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences) ;
  • Alizadeh-Navaei, Reza (Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences) ;
  • Abedini, Ehsan (Health Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences)
  • Received : 2017.06.08
  • Accepted : 2019.01.21
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Investigating the survival of patients with cancer is vitally necessary for controlling the disease and for assessing treatment methods. This study aimed to compare various statistical models of survival and to determine the survival rate and its related factors among patients suffering from lung cancer. Methods: In this retrospective cohort, the cumulative survival rate, median survival time, and factors associated with the survival of lung cancer patients were estimated using Cox, Weibull, exponential, and Gompertz regression models. Kaplan-Meier tables and the log-rank test were also used to analyze the survival of patients in different subgroups. Results: Of 102 patients with lung cancer, 74.5% were male. During the follow-up period, 80.4% died. The incidence rate of death among patients was estimated as 3.9 (95% confidence [CI], 3.1 to 4.8) per 100 person-months. The 5-year survival rate for all patients, males, females, patients with non-small cell lung carcinoma (NSCLC), and patients with small cell lung carcinoma (SCLC) was 17%, 13%, 29%, 21%, and 0%, respectively. The median survival time for all patients, males, females, those with NSCLC, and those with SCLC was 12.7 months, 12.0 months, 16.0 months, 16.0 months, and 6.0 months, respectively. Multivariate analyses indicated that the hazard ratios (95% CIs) for male sex, age, and SCLC were 0.56 (0.33 to 0.93), 1.03 (1.01 to 1.05), and 2.91 (1.71 to 4.95), respectively. Conclusions: Our results showed that the exponential model was the most precise. This model identified age, sex, and type of cancer as factors that predicted survival in patients with lung cancer.

Keywords

References

  1. Abazari M, Gholamnejad M, Roshanaei G, Abazari R, Roosta Y, Mahjub H. Estimation of survival rates in patients with lung cancer in west Azerbaijan, the northwest of Iran. Asian Pac J Cancer Prev 2015;16(9):3923-3926. https://doi.org/10.7314/APJCP.2015.16.9.3923
  2. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. The incidence and mortality of lung cancer and their relationship to development in Asia. Transl Lung Cancer Res 2015;4(6):763-774.
  3. Rafiemanesh H, Mehtarpour M, Khani F, Hesami SM, Shamlou R, Towhidi F, et al. Epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world. J Thorac Dis 2016;8(6):1094-1102. https://doi.org/10.21037/jtd.2016.03.91
  4. Luchtenborg M, Riaz SP, Lim E, Page R, Baldwin DR, Jakobsen E, et al. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009. Thorax 2014;69(3): 269-273. https://doi.org/10.1136/thoraxjnl-2013-203884
  5. Sen E, Kaya A, Erol S, Savas I, Gonullu U. Lung cancer in women: clinical features and factors related to survival. Tuberk Toraks 2008;56(3):266-274 (Turkish).
  6. Zhang C, Yang H, Zhao H, Lang B, Yu X, Xiao P, et al. Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience. J Thorac Dis 2017;9(1): 151-158. https://doi.org/10.21037/jtd.2017.01.07
  7. Kukulj S, Popovic F, Budimir B, Drpa G, Serdarevic M, Polic-Vizintin M. Smoking behaviors and lung cancer epidemiology: a cohort study. Psychiatr Danub 2014;26 Suppl 3:485-489.
  8. Prim JM, Barcala FJ, Esquete JP, Reino AP, Lopez AF, Cuadrado LV. Lung cancer in a health area of Spain: incidence, characteristics and survival. Eur J Cancer Care (Engl) 2010;19(2):227-233. https://doi.org/10.1111/j.1365-2354.2008.01008.x
  9. Svensson G, Ewers SB, Ohlsson O, Olsson H. Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender. Clin Respir J 2013;7(1):91-100. https://doi.org/10.1111/j.1752-699X.2012.00289.x
  10. Biswas T, Walker P, Podder T, Rosenman J, Efird J. Important prognostic factors for lung cancer in tobacco predominant Eastern North Carolina: study based on a single cancer registry. Lung Cancer 2014;84(2):116-120. https://doi.org/10.1016/j.lungcan.2014.01.026
  11. Ball D, Thursfield V, Irving L, Mitchell P, Richardson G, Torn-Broers Y, et al. Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: a cancer registry study. Lung Cancer 2013;82(2):358-361. https://doi.org/10.1016/j.lungcan.2013.08.011
  12. Zahir ST, Mirtalebi M. Survival of patients with lung cancer, Yazd, Iran. Asian Pac J Cancer Prev 2012;13(9):4387-4391. https://doi.org/10.7314/APJCP.2012.13.9.4387
  13. Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM, et al. Five year survival for lung cancer patients managed in general hospitals. Rev Mal Respir 2009;26(1):37-44 (French). https://doi.org/10.1016/S0761-8425(09)70132-9

Cited by

  1. Immune Infiltration Profiling in Nonsmall Cell Lung Cancer and Their Clinical Significance: Study Based on Gene Expression Measurements vol.38, pp.11, 2019, https://doi.org/10.1089/dna.2019.4899
  2. Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment vol.13, pp.4, 2019, https://doi.org/10.3390/cancers13040775